ZA200107965B - Process for preparing amine platinum complexes. - Google Patents
Process for preparing amine platinum complexes. Download PDFInfo
- Publication number
- ZA200107965B ZA200107965B ZA200107965A ZA200107965A ZA200107965B ZA 200107965 B ZA200107965 B ZA 200107965B ZA 200107965 A ZA200107965 A ZA 200107965A ZA 200107965 A ZA200107965 A ZA 200107965A ZA 200107965 B ZA200107965 B ZA 200107965B
- Authority
- ZA
- South Africa
- Prior art keywords
- solvent
- amine
- carboxylate
- hydroxy
- halogen
- Prior art date
Links
- -1 amine platinum complexes Chemical class 0.000 title claims description 37
- 238000004519 manufacturing process Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims description 142
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims description 132
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 104
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 97
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 90
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 63
- 230000015572 biosynthetic process Effects 0.000 claims description 59
- 239000002904 solvent Substances 0.000 claims description 58
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 52
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 47
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 46
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 43
- 150000001412 amines Chemical class 0.000 claims description 42
- 229910052697 platinum Inorganic materials 0.000 claims description 33
- 150000007942 carboxylates Chemical group 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical group 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- 150000004820 halides Chemical class 0.000 claims description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- 229940043279 diisopropylamine Drugs 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 12
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 12
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 10
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 10
- 239000000010 aprotic solvent Substances 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 150000004703 alkoxides Chemical class 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 5
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 5
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 150000003057 platinum Chemical class 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 claims description 2
- 150000003973 alkyl amines Chemical class 0.000 claims description 2
- YUENFNPLGJCNRB-UHFFFAOYSA-N anthracen-1-amine Chemical compound C1=CC=C2C=C3C(N)=CC=CC3=CC2=C1 YUENFNPLGJCNRB-UHFFFAOYSA-N 0.000 claims description 2
- 150000004982 aromatic amines Chemical class 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- 150000002916 oxazoles Chemical class 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 150000003217 pyrazoles Chemical class 0.000 claims description 2
- 150000004992 toluidines Chemical class 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000007800 oxidant agent Substances 0.000 claims 4
- 230000001590 oxidative effect Effects 0.000 claims 4
- 150000001805 chlorine compounds Chemical group 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 101100288554 Mus musculus Lcor gene Proteins 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 81
- 238000006243 chemical reaction Methods 0.000 description 72
- 239000000243 solution Substances 0.000 description 47
- 238000003786 synthesis reaction Methods 0.000 description 44
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 40
- 239000002244 precipitate Substances 0.000 description 35
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 31
- 238000005481 NMR spectroscopy Methods 0.000 description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 239000011521 glass Substances 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 238000003828 vacuum filtration Methods 0.000 description 13
- 230000014759 maintenance of location Effects 0.000 description 12
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 12
- LCZUOKDVTBMCMX-UHFFFAOYSA-N 2,5-Dimethylpyrazine Chemical compound CC1=CN=C(C)C=N1 LCZUOKDVTBMCMX-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000000908 ammonium hydroxide Substances 0.000 description 7
- 239000006227 byproduct Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 229910019029 PtCl4 Inorganic materials 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 239000004570 mortar (masonry) Substances 0.000 description 6
- 229910052709 silver Inorganic materials 0.000 description 6
- 239000004332 silver Substances 0.000 description 6
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 6
- FBEIPJNQGITEBL-UHFFFAOYSA-J tetrachloroplatinum Chemical compound Cl[Pt](Cl)(Cl)Cl FBEIPJNQGITEBL-UHFFFAOYSA-J 0.000 description 6
- 239000001934 2,5-dimethylpyrazine Substances 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- OXQOBQJCDNLAPO-UHFFFAOYSA-N 2,3-Dimethylpyrazine Chemical compound CC1=NC=CN=C1C OXQOBQJCDNLAPO-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 150000003222 pyridines Chemical class 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- LSBIUXKNVUBKRI-UHFFFAOYSA-N 4,6-dimethylpyrimidine Chemical compound CC1=CC(C)=NC=N1 LSBIUXKNVUBKRI-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- BSNMHJLEPWOFMH-UHFFFAOYSA-N azanium;acetate;trihydrate Chemical compound [NH4+].O.O.O.CC([O-])=O BSNMHJLEPWOFMH-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- 238000004294 195Pt NMR spectroscopy Methods 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910018944 PtBr2 Inorganic materials 0.000 description 1
- 229910019032 PtCl2 Inorganic materials 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- KGRJUMGAEQQVFK-UHFFFAOYSA-L platinum(2+);dibromide Chemical compound Br[Pt]Br KGRJUMGAEQQVFK-UHFFFAOYSA-L 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12893999P | 1999-04-13 | 1999-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200107965B true ZA200107965B (en) | 2003-01-02 |
Family
ID=22437722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200107965A ZA200107965B (en) | 1999-04-13 | 2001-09-27 | Process for preparing amine platinum complexes. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6518428B1 (xx) |
| EP (1) | EP1165576B1 (xx) |
| JP (1) | JP4756669B2 (xx) |
| KR (1) | KR100711955B1 (xx) |
| CN (3) | CN100460412C (xx) |
| AR (1) | AR043084A1 (xx) |
| AT (1) | ATE309257T1 (xx) |
| AU (1) | AU770006B2 (xx) |
| BG (1) | BG65429B1 (xx) |
| BR (1) | BR0009780B1 (xx) |
| CA (1) | CA2368849C (xx) |
| CY (1) | CY1104965T1 (xx) |
| CZ (1) | CZ303156B6 (xx) |
| DE (1) | DE60023859T2 (xx) |
| DK (1) | DK1165576T3 (xx) |
| EE (1) | EE04747B1 (xx) |
| ES (1) | ES2253214T3 (xx) |
| HK (2) | HK1039336B (xx) |
| HU (1) | HUP0200748A3 (xx) |
| IL (1) | IL145671A0 (xx) |
| IS (1) | IS2709B (xx) |
| MX (1) | MXPA01010430A (xx) |
| MY (1) | MY122706A (xx) |
| NO (1) | NO330429B1 (xx) |
| NZ (1) | NZ514736A (xx) |
| PL (1) | PL202731B1 (xx) |
| RU (1) | RU2245340C2 (xx) |
| SK (1) | SK286374B6 (xx) |
| TW (1) | TWI289565B (xx) |
| UA (1) | UA71614C2 (xx) |
| WO (1) | WO2000061590A1 (xx) |
| ZA (1) | ZA200107965B (xx) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9502799D0 (en) * | 1995-02-14 | 1995-04-05 | Johnson Matthey Plc | Improvements in platinum complexes |
| IL145671A0 (en) | 1999-04-13 | 2002-06-30 | Anormed Inc | Process for preparing amine platinum complexes |
| US6413953B1 (en) * | 1999-04-13 | 2002-07-02 | Anormed Inc. | Pt(IV) antitumor agent |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| US6806289B1 (en) * | 2000-07-14 | 2004-10-19 | Stephen J. Lippard | Coordination complexes, and methods for preparing by combinatorial methods, assaying and using the same |
| US6894049B1 (en) * | 2000-10-04 | 2005-05-17 | Anormed, Inc. | Platinum complexes as antitumor agents |
| DE602005007471D1 (de) | 2004-02-18 | 2008-07-24 | Gpc Biotech Ag | Satraplatin zur behandlung von resistenten oder refrkatären tumoren |
| CZ296459B6 (cs) * | 2004-09-14 | 2006-03-15 | Pliva-Lachema A. S. | Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo |
| ES2257178B1 (es) * | 2004-09-30 | 2007-08-16 | Universidad Autonoma De Madrid | Compuestos de platino de formula trans-(ptc12(isopropilamina)(4-(hidroximetil)-piridina)) y trans-(ptc12(isopropilamina)(3-hidroximetil)-piridina y su aplicacion como farmaco antitumoral. |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| WO2009011861A1 (en) * | 2007-07-16 | 2009-01-22 | Poniard Pharmaceuticals, Inc. | Oral formulations for picoplatin |
| WO2009099634A2 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Picoplatin and amrubicin to treat lung cancer |
| CN102448310A (zh) * | 2009-06-12 | 2012-05-09 | 铂雅制药公司 | 吡铂的改进合成 |
| RU2451010C1 (ru) * | 2011-01-11 | 2012-05-20 | Закрытое Акционерное Общество "Ива Фарм" | Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия |
| CN103554188B (zh) * | 2013-11-19 | 2016-03-02 | 辽宁大学 | 6-(氮杂环取代)蒽醌二氯化铂配合物及其制备方法和应用 |
| CN103860539B (zh) * | 2014-04-14 | 2016-02-10 | 于迎涛 | 一种具有混合轴向配体的Pt（IV）类抗癌药物及制备方法 |
| CN104231000A (zh) * | 2014-08-20 | 2014-12-24 | 山东铂源药业有限公司 | 一种抗肿瘤药物甲啶铂的合成方法 |
| US10987353B2 (en) | 2016-05-04 | 2021-04-27 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs |
| KR102137669B1 (ko) * | 2019-08-05 | 2020-07-27 | 한국과학기술연구원 | 메탄올 또는 그 전구체 합성용 촉매, 이의 제조방법 및 이를 이용한 메탄올 또는 그 전구체의 제조방법 |
| JP2023533060A (ja) | 2020-07-08 | 2023-08-01 | デイトン・セラピューティクス・アクチェンゲゼルシャフト | リンパ系組織の悪性腫瘍 |
| CN113402565B (zh) * | 2021-06-16 | 2023-07-28 | 中国人民解放军空军军医大学 | 一类含有泊沙康唑的四价铂配合物、制备方法及其应用 |
| MX2024008510A (es) | 2022-01-07 | 2024-08-15 | Pharma& Schweiz Gmbh | Tratamiento de neoplasias malignas hematologicas por medio de satraplatino. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4329299A (en) * | 1979-08-23 | 1982-05-11 | Johnson, Matthey & Co., Limited | Composition of matter containing platinum |
| US4533502A (en) | 1983-02-22 | 1985-08-06 | Rochon Fernande D | Platinum (II) compounds and their preparation |
| EP0167310B1 (en) * | 1984-06-27 | 1991-05-29 | Johnson Matthey Public Limited Company | Platinum co-ordination compounds |
| US5244919A (en) | 1988-02-02 | 1993-09-14 | Johnson Matthey, Inc. | Pt(IV) complexes as anti-tumor agents |
| GB9105037D0 (en) | 1991-03-09 | 1991-04-24 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9502799D0 (en) * | 1995-02-14 | 1995-04-05 | Johnson Matthey Plc | Improvements in platinum complexes |
| US5547982A (en) | 1995-02-27 | 1996-08-20 | Johnson Matthey, Inc. | Anti-tumor platinum complexes |
| CN1391577A (zh) | 1999-03-19 | 2003-01-15 | 阿诺麦德股份有限公司 | 含金属复合物的药物组合物 |
| IL145671A0 (en) | 1999-04-13 | 2002-06-30 | Anormed Inc | Process for preparing amine platinum complexes |
-
2000
- 2000-04-11 IL IL14567100A patent/IL145671A0/xx not_active IP Right Cessation
- 2000-04-11 ES ES00918620T patent/ES2253214T3/es not_active Expired - Lifetime
- 2000-04-11 CN CNB2006100093181A patent/CN100460412C/zh not_active Expired - Lifetime
- 2000-04-11 DE DE60023859T patent/DE60023859T2/de not_active Expired - Lifetime
- 2000-04-11 PL PL351612A patent/PL202731B1/pl not_active IP Right Cessation
- 2000-04-11 RU RU2001130457/04A patent/RU2245340C2/ru not_active IP Right Cessation
- 2000-04-11 CA CA2368849A patent/CA2368849C/en not_active Expired - Fee Related
- 2000-04-11 AU AU39510/00A patent/AU770006B2/en not_active Expired
- 2000-04-11 CN CN2006101003981A patent/CN1916009B/zh not_active Expired - Lifetime
- 2000-04-11 HU HU0200748A patent/HUP0200748A3/hu unknown
- 2000-04-11 SK SK1468-2001A patent/SK286374B6/sk not_active IP Right Cessation
- 2000-04-11 JP JP2000610861A patent/JP4756669B2/ja not_active Expired - Fee Related
- 2000-04-11 NZ NZ514736A patent/NZ514736A/xx not_active IP Right Cessation
- 2000-04-11 KR KR1020017013049A patent/KR100711955B1/ko not_active IP Right Cessation
- 2000-04-11 EE EEP200100536A patent/EE04747B1/xx not_active IP Right Cessation
- 2000-04-11 US US09/547,074 patent/US6518428B1/en not_active Expired - Lifetime
- 2000-04-11 AT AT00918620T patent/ATE309257T1/de active
- 2000-04-11 CZ CZ20013648A patent/CZ303156B6/cs not_active IP Right Cessation
- 2000-04-11 WO PCT/CA2000/000385 patent/WO2000061590A1/en active IP Right Grant
- 2000-04-11 EP EP00918620A patent/EP1165576B1/en not_active Expired - Lifetime
- 2000-04-11 MX MXPA01010430A patent/MXPA01010430A/es active IP Right Grant
- 2000-04-11 DK DK00918620T patent/DK1165576T3/da active
- 2000-04-11 BR BRPI0009780-2B1A patent/BR0009780B1/pt not_active IP Right Cessation
- 2000-04-11 CN CNB008076359A patent/CN1250559C/zh not_active Expired - Fee Related
- 2000-04-12 AR ARP000101696A patent/AR043084A1/es active IP Right Grant
- 2000-04-12 MY MYPI20001537A patent/MY122706A/en unknown
- 2000-06-23 TW TW089112556A patent/TWI289565B/zh not_active IP Right Cessation
- 2000-11-04 UA UA2001117756A patent/UA71614C2/uk unknown
-
2001
- 2001-09-27 ZA ZA200107965A patent/ZA200107965B/en unknown
- 2001-09-28 IS IS6092A patent/IS2709B/is unknown
- 2001-10-12 NO NO20014957A patent/NO330429B1/no not_active IP Right Cessation
- 2001-11-08 BG BG106090A patent/BG65429B1/bg unknown
-
2002
- 2002-02-04 HK HK02100835.7A patent/HK1039336B/zh unknown
-
2006
- 2006-02-01 CY CY20061100130T patent/CY1104965T1/el unknown
-
2007
- 2007-08-01 HK HK07108382.2A patent/HK1100562A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1165576B1 (en) | Process for preparing amine platinum complexes | |
| Casini et al. | Synthesis, characterisation and biological properties of gold (III) compounds with modified bipyridine and bipyridylamine ligands | |
| IE56937B1 (en) | Platinum(ii)compounds and their preparation | |
| HU224716B1 (en) | Platinum complex, its preparation and therapeutic application | |
| CA2241992A1 (en) | Terpyridine-platinum(ii) complexes | |
| MX2007002453A (es) | Preparacion de complejos de platino (ii). | |
| Wang et al. | Synthesis of isomers of organotin substituted polyoxotungstates and comparison of the antitumor activity of isomers | |
| EP2243773A1 (en) | Platinum complex compound and utilization of the same | |
| Siebel et al. | Analogues of Cis‐and Transplatin with a Rich Solution Chemistry: cis‐[PtCl2 (NH3)(1‐MeC‐N3)] and trans‐[PtI2 (NH3)(1‐MeC‐N3)] | |
| Bernges et al. | Ring‐substituted diaqua (1, 2‐diphenylethylenediamine) platinum (II) sulfate reacts with DNA through a dissociable complex | |
| Pullen et al. | On the Heterogeneous Nature of Cisplatin‐1‐Methyluracil Complexes: Coexistence of Different Aggregation Modes and Partial Loss of NH3 Ligands as Likely Explanation | |
| WO1998020013A1 (de) | Neue knoevenagel-kondensationsprodukte, verfahren zu deren herstellung und verwendung | |
| Dey et al. | Multiple coordination modes of hemilabile 3-dimethylaminopropyl chalcogenolates in platinum (II) complexes: Synthesis, spectroscopy and structures | |
| Dong et al. | Anionopentaaminecobalt (III) complexes with polyamine ligands. XII. Geometric and chiral interconversions associated with the coordination of N-methyl-1, 3-diaminopropane in Isomers of chloro and aqua (N-methyl-1, 3-diaminopropane)(diethylenetriamine) cobalt (III) complexes | |
| MAEDA et al. | SYNTHESIS AND ANTITUMOR ACTIVITY OF SELENO-AND THIOPURINES COMPLEXED WITH cis-DIAMMINOPLATINUM (II) | |
| Ren et al. | Synthesis and characterization of monodeoxynucleotide tethered platinum-(II) and-(IV) complexes | |
| Coffey et al. | Replacement of imido by disulfido at the molybdenum (VI) centre: reactivity of bis (imido) complexes [Mo (η2-S2CNEt2) 2 (NR) 2] with hydrogen sulfide and Lawesson's reagent: X-ray crystal structure of [Mo (η2-S2CNEt2) 2 (η2-S2)(N-2, 6-Cl2C6H3)] | |
| Hess | Interactions of dinuclear transition metal complexes with amino acids, nucleotides, and DNA |